One of the more common patterns Aventria sees when speaking with laboratories is that a sample is often described as having been “stored correctly” simply because it was kept cold. In practice, that description can hide the variable that mattered most: not the nominal storage temperature, but the number, magnitude, and timing of the temperature excursions the sample experienced before analysis. For viable cells, that can mean a measurable drop in recovery or function. For blood, tissue, and molecular samples, it can mean changes that are subtle enough to pass initial handling checks but large enough to distort downstream data. This is one of the reasons temperature control should be treated as a physical systems problem, not just a storage problem.

Temperature fluctuations matter because biological samples are not uniformly sensitive to thermal stress. Viable cells are especially vulnerable because cooling, warming, and rewarming alter membrane integrity, osmotic balance, intracellular ice formation, and ice recrystallization dynamics. Mazur’s classic work established the central cryobiology principle that excessively rapid cooling can drive lethal intracellular freezing, while later work has shown that warming conditions can be just as important because recrystallization during thawing or transient warming damages cells even when the initial freezing step appeared successful. In other words, a sample can be frozen “correctly” and still lose viability because the thermal path around storage and recovery was poorly controlled.

That general principle is borne out in direct studies of cryogenic temperature excursions. Germann and colleagues reported that cyclical temperature shifts during deep-temperature storage reduced peripheral blood mononuclear cell recovery, viability, and antigen-specific T-cell responses. Pogozhykh and co-workers similarly found that temperature fluctuations during cryopreservation affected survival and functional parameters in several cell types. These findings are important because they move the discussion beyond simple post-thaw viability percentages: thermal instability does not only reduce the number of surviving cells, it can also alter the biological performance of the cells that remain.

Controlled freezing is therefore not a procedural nicety but a determinant of sample quality. A substantial body of cryobiology literature shows that cooling rate governs the balance between intracellular ice formation and solution effects injury, and more recent work has demonstrated that transfer conditions into long-term storage also matter. Kilbride et al. showed that for several mammalian cell lines, cooling needed to remain controlled to around −40 °C before transfer to long-term cryogenic storage to achieve optimal recovery. Daily et al. further showed that controlling nucleation reduced supercooling and variability in cryopreserved mammalian cells. Together, these studies support the use of controlled-rate freezers, controlled nucleation approaches, and validated handoff points into cryogenic storage rather than ad hoc freezing workflows.

Long-term storage temperature also has a physical basis. Hubel and co-authors, and Shabihkhani et al., note that storage below the glass transition region of aqueous systems, commonly discussed around −137 °C, markedly reduces molecular mobility and therefore reduces the degradative processes that continue to occur at warmer temperatures. That does not mean every sample must be stored identically, but it does mean that “frozen” is not a single condition. A sample stored at −80 °C and one stored in a properly maintained cryogenic environment are not exposed to the same physical regime, and the difference becomes more important as storage duration increases or as the sample type becomes more thermally fragile.

Outside cryogenic workflows, the effect of temperature variability remains significant, particularly for nucleic acids. Whole-blood RNA is notably sensitive to preanalytical storage conditions. Huang et al. reported clear quality decline with longer storage and found that low-temperature storage did not fully prevent RNA degradation, while freezing whole blood was particularly damaging. Shen et al. likewise showed that blood storage conditions affected RNA integrity and gene expression readouts, in part because cells remain metabolically active or undergo apoptosis during pre-processing delays. More recent work has further quantified allowable windows, showing that blood RNA quality remains acceptable only within limited time-temperature ranges. The implication is straightforward: delayed handling at 4 °C is not biologically neutral, and uncontrolled transitions between room temperature, refrigeration, and freezing can alter the molecular state of the sample before extraction even begins.

Temperature sensitivity is not identical across all analytes, which is precisely why equipment decisions should be matched to sample type rather than generalized from one workflow to another. For some serum and plasma biomarkers, a single freeze-thaw cycle may have little practical effect. Abraham et al. found that one freeze-thaw cycle after storage at −70 °C produced only small changes for the biomarkers they studied, remaining within acceptable limits. By contrast, Mitchell et al. showed that repeated freeze-thaw cycles and storage history affected plasma samples used for mass spectrometry-based biomarker discovery. The correct conclusion is not that freeze-thaw is always catastrophic or always benign, but that susceptibility is analyte-specific, platform-specific, and highly dependent on how many excursions occur and how the sample is used downstream.

This is where physical error reduction becomes an equipment question. If viable cells are being preserved, the evidence supports controlled-rate freezing, validated transition into long-term storage, stable cryogenic storage conditions, and rapid, uniform thawing to limit recrystallization injury. If blood or tissue samples are being collected for molecular analysis, the key controls are rapid handoff into the correct storage condition, minimization of pre-processing delay, and elimination of unnecessary transitions between ambient, refrigerated, and frozen states. If samples are likely to be re-used, aliquoting is usually preferable to repeated thaw-refreeze exposure because repeated thermal cycling is itself a source of instability. These are not merely workflow preferences; they are interventions directly supported by the literature on sample integrity.

For laboratories buying or upgrading infrastructure, the practical lesson is that freezer temperature alone is too crude a proxy for sample protection. The more useful questions are whether the freezing step is rate-controlled, whether the storage regime minimizes excursions during access, whether transport hardware prevents transient warming, whether thawing is standardized, and whether the monitoring system captures real sample risk rather than only chamber air temperature. In laboratories handling cell-based materials, those distinctions can determine post-thaw recovery and function. In molecular workflows, they can determine whether the extracted analyte still reflects the biology that was originally sampled.

The broader point, and the one that tends to recur in Aventria’s technical discussions with laboratories, is that temperature control is rarely just a storage line item. It is part of the measurement system. A freezer, cryogenic vessel, transport shipper, controlled-rate freezer, or monitored thawing workflow is not protecting sample quality in an abstract sense; it is protecting the validity of the result that comes later. Where temperature excursions are common, sample viability and analytical integrity become less a function of assay design and more a function of physical handling. The literature is consistent on that point, even if the exact failure mode differs between cells, RNA, proteins, and tissues.

References

Mazur P. Freezing of living cells: mechanisms and implications. American Journal of Physiology, 1984.

Germann A, Oh YJ, Schmidt T, et al. Temperature fluctuations during deep temperature cryopreservation reduce PBMC recovery, viability and T-cell function. Cryobiology, 2013.

Pogozhykh D, et al. Influence of temperature fluctuations during cryopreservation on stem cells and derivatives. Stem Cell Research & Therapy, 2017.

Kilbride P, et al. The transfer temperature from slow cooling to cryogenic storage is critical for optimal recovery of cryopreserved mammalian cells. PLOS ONE, 2021.

Hubel A, Spindler R, Skubitz APN. Storage of human biospecimens: selection of the optimal storage temperature. Biopreservation and Biobanking, 2014.

Shabihkhani M, et al. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens. Biopreservation and Biobanking, 2014.

Huang LH, et al. The effects of storage temperature and duration of blood samples on DNA and RNA qualities. PLoS ONE, 2017.

Shen Y, et al. Impact of RNA integrity and blood sample storage conditions on gene expression. Frontiers, 2018.

Jiang Z, et al. Effects of storage temperature, storage time, and hemolysis on blood sample RNA quality. Heliyon, 2023.

Mitchell BL, et al. Impact of freeze-thaw cycles and storage time on plasma samples used in mass spectrometry-based biomarker discovery projects. Cancer Informatics, 2007.

Abraham RA, et al. The effects of a single freeze-thaw cycle on concentrations of nutritional, noncommunicable disease, and inflammatory biomarkers in serum samples. Journal of Laboratory Physicians, 2021.

Uhrig M, et al. Improving cell recovery: freezing and thawing optimization of hPSC-derived cells. Cells, 2022.